Cargando…
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and ph...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873121/ https://www.ncbi.nlm.nih.gov/pubmed/33507525 http://dx.doi.org/10.1007/s40263-020-00779-5 |
_version_ | 1783649328598876160 |
---|---|
author | Correll, Christoph U. Kim, Edward Sliwa, Jennifer Kern Hamm, Wayne Gopal, Srihari Mathews, Maju Venkatasubramanian, Raja Saklad, Stephen R. |
author_facet | Correll, Christoph U. Kim, Edward Sliwa, Jennifer Kern Hamm, Wayne Gopal, Srihari Mathews, Maju Venkatasubramanian, Raja Saklad, Stephen R. |
author_sort | Correll, Christoph U. |
collection | PubMed |
description | The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics that have implications for medication selection, administration interval, and injection site. This review outlines key differences in drug formulations and pharmacokinetics among LAI antipsychotics. A systematic search of the PubMed database was conducted to identify physical and formulation properties and pharmacokinetic data of commercially available LAI antipsychotics, including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres. Additional information was obtained from package inserts and product monographs. Relevant data on drug properties, administration details, pharmacokinetic parameters, and oral dose equivalencies of LAI antipsychotics are summarized. Based on our analysis, formulation characteristics (e.g., vehicle medium) and administration characteristics (e.g., injection site) can affect rate of absorption and adverse effects and may factor into whether oral supplementation or an additional injection is needed. Dose adjustments may be necessary based on potential drug–drug interactions, and approximate dose equivalence with oral formulations can help inform titration when switching from oral to LAI formulations. Clinicians administering LAI antipsychotics should consider these formulation and pharmacokinetic factors to maximize clinical impact and to adjust to an individual patient’s needs and treatment goals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-020-00779-5. |
format | Online Article Text |
id | pubmed-7873121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78731212021-02-22 Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview Correll, Christoph U. Kim, Edward Sliwa, Jennifer Kern Hamm, Wayne Gopal, Srihari Mathews, Maju Venkatasubramanian, Raja Saklad, Stephen R. CNS Drugs Review Article The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics that have implications for medication selection, administration interval, and injection site. This review outlines key differences in drug formulations and pharmacokinetics among LAI antipsychotics. A systematic search of the PubMed database was conducted to identify physical and formulation properties and pharmacokinetic data of commercially available LAI antipsychotics, including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres. Additional information was obtained from package inserts and product monographs. Relevant data on drug properties, administration details, pharmacokinetic parameters, and oral dose equivalencies of LAI antipsychotics are summarized. Based on our analysis, formulation characteristics (e.g., vehicle medium) and administration characteristics (e.g., injection site) can affect rate of absorption and adverse effects and may factor into whether oral supplementation or an additional injection is needed. Dose adjustments may be necessary based on potential drug–drug interactions, and approximate dose equivalence with oral formulations can help inform titration when switching from oral to LAI formulations. Clinicians administering LAI antipsychotics should consider these formulation and pharmacokinetic factors to maximize clinical impact and to adjust to an individual patient’s needs and treatment goals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-020-00779-5. Springer International Publishing 2021-01-28 2021 /pmc/articles/PMC7873121/ /pubmed/33507525 http://dx.doi.org/10.1007/s40263-020-00779-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Article Correll, Christoph U. Kim, Edward Sliwa, Jennifer Kern Hamm, Wayne Gopal, Srihari Mathews, Maju Venkatasubramanian, Raja Saklad, Stephen R. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title_full | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title_fullStr | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title_full_unstemmed | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title_short | Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview |
title_sort | pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873121/ https://www.ncbi.nlm.nih.gov/pubmed/33507525 http://dx.doi.org/10.1007/s40263-020-00779-5 |
work_keys_str_mv | AT correllchristophu pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT kimedward pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT sliwajenniferkern pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT hammwayne pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT gopalsrihari pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT mathewsmaju pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT venkatasubramanianraja pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview AT sakladstephenr pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview |